← All trials
NCT03860857
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2018
- Primary completion
- Dec 22, 2023
- Completion date
- Dec 22, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 9 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, IrvineLead sponsor
- National Institute on Aging (NIA)Collaborator
- University of California, IrvineStudy director
- University of California, IrvineOverall official - principal investigator
- University of California, IrvineReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.